Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example
| Autor: | Arlene R Hughes, Cynthia H Brothers, Michael Mosteller, William R Spreen, Daniel K Burns |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
Research design medicine.medical_specialty MEDLINE Pharmacology law.invention Drug Hypersensitivity Randomized controlled trial law Abacavir Internal medicine Genetics medicine Humans Prospective Studies Adverse effect Prospective cohort study Retrospective Studies business.industry Retrospective cohort study Dideoxynucleosides Phenotype HLA-B Antigens Research Design Reverse Transcriptase Inhibitors Molecular Medicine business Pharmacogenetics medicine.drug |
| Zdroj: | Pharmacogenomics. 10:225-233 |
| ISSN: | 1744-8042 1462-2416 |
| Popis: | Abacavir hypersensitivity (ABC HSR) is a treatment-limiting adverse event associated with the use of the antiretroviral medicine, abacavir. The objective of the ABC HSR pharmacogenetics program was to identify clinically useful genetic risk factors to predict an individual patient’s risk for ABC HSR. The major histocompatibility complex allele, HLA-B*5701, was identified retrospectively and confirmed with independent sample sets. The clinical utility of prospective HLA-B*5701 screening was demonstrated in a blinded randomized clinical trial and in open-label cohorts. Screening has been incorporated into clinical practice and the ABC HSR pharmacogenetics program has been highlighted as a success by pharmacogenetics researchers. Important lessons from this pharmacogenetics program will be discussed in this paper. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|